Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 4,225 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: HIV Infections
Interventions: PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Overweight, Obesity
Interventions: pramlintide acetate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 25 Years to 60 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 10
States / cities: Chula Vista, California • Long Beach, California • San Diego, California + 7 more

Conditions: Gastroenteritis
Interventions: HIL-214, Placebo; Biological
Lead sponsor: HilleVax; Industry
Eligibility: 5 Months to 5 Months
Enrollment: 3,084 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rotator Cuff Tears
Interventions: Testosterone cypionate, Placebos; Drug
Lead sponsor: Orthopedic Institute, Sioux Falls, SD; Other
Eligibility: 45 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Lichen Simplex Chronicus
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 12
States / cities: Anaheim, California • Fremont, California • Miami, Florida + 9 more

Conditions: Endometriosis
Interventions: Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Gainesville, Florida + 22 more

Conditions: Heart Failure
Interventions: Anakinra, Placebo; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Charlottesville, Virginia • Richmond, Virginia

Conditions: Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia
Interventions: Benralizumab, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C
Interventions: Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 32
States / cities: Beverly Hills, California • Oakland, California • San Diego, California + 23 more

Conditions: Cytomegalovirus Infections
Interventions: TCN-202, Placebo; Biological
Lead sponsor: Theraclone Sciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoarthritis, Knee
Interventions: GID SVF-2 Device System; Device
Lead sponsor: GID BIO, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: Sacramento, California • Coral Springs, Florida • New Orleans, Louisiana + 6 more

Conditions: Vitreomacular Adhesion
Interventions: 125 µg Ocriplasmin, Placebo; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 35 more

Conditions: Obesity
Interventions: Leptin, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 67 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Higher-risk Myelodysplastic Syndromes
Interventions: AK117, Placebo, Azacitidine; Drug
Lead sponsor: Akeso; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 11 more

Conditions: Migraine
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 178
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more

Conditions: Acute HIV Infection
Interventions: VRC07-523LS, PGT121.414.LS, Placebo, ART; Biological · Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Hidradenitis Suppurativa
Interventions: etanercept; Drug
Lead sponsor: Penn State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 15 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Williamsville, New York

Conditions: Atopic Dermatitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Fountain Valley, California • Los Angeles, California • Tampa, Florida + 14 more

Conditions: Aging
Interventions: Placebo, Nutritional Supplement, In-home exercise, Testosterone; Drug · Dietary Supplement · Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 65 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Galveston, Texas

Conditions: Normal Physiology
Interventions: Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
Interventions: Galvokimig, Placebo; Biological
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Encino, California • Westminster, California • Miami, Florida + 13 more

Conditions: Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions: Lonapegsomatropin, Placebo, Somatropin; Drug · Other
Lead sponsor: Ascendis Pharma Endocrinology Division A/S; Industry
Eligibility: 23 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more

Conditions: Crohn's Disease
Interventions: Brazikumab IV Infusion, Brazikumab SC Injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 52
States / cities: Phoenix, Arizona • Lone Tree, Colorado • Clearwater, Florida + 25 more

Search by objective public record fields.

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects

Efficacy and Safety of Two Doses of HIL-214 in Children

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

Bay98-7196, Dose Finding / POC Study

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis

Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

Leptin in the Maintenance of Reduced Body Weight

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Treatment of Hidradenitis Suppurativa Using Etanercept

Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease